Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ILK | Q13418 | 6/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398344 | 0.76 | KDM4E (0.51) | KDM4ERAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL29808854 | 0.76 | KDM4E (0.62) | KDM4ERAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL2846634 | 0.76 | KDM4E (0.62) | KDM4ERAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL7081757 | 0.75 | APP (0.41) | APP | |
| SCHEMBL4623912 | 0.75 | METAP2 (0.35) | KDM4ENPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL231307 | 0.75 | KDM4E (0.75) | KDM4ERAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6185136 | 0.74 | NPC1 (0.45) | KDM4ERAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6746143 | 0.74 | NPC1 (0.55) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12854008 | 0.73 | KDM4E (0.72) | KDM4ERAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL787341 | 0.72 | KDM4E (0.50) | KDM4ERAB9ANPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0235198-B1 | COLORED UNSATURATED POLYESTER MATERIAL CONTAINING COPOLYMERIZED METHINE DYES, AND PRODUCTS THEREFROM | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0215054-B1 | CONDENSATION POLYMERS AND PRODUCTS THEREFROM | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-01-03 | — | — | EP | claimed |
| EP-3083600-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica NV (BE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015095011-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-25 | — | — | WO | disclosed |
| EP-1391454-B1 | Substituted benzamide compounds with antihypertensive activity | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1641775-B1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | disclosed |
| US-20060235055-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2006-10-19 | — | — | US | disclosed |
| EP-1641775-A1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | Euro-Celtique S.A. (LU) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005007641-A1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235055-A1 | Therapeutic agents useful for treating pain | CHRNA10, ACHE, SNCA | KDM4E 1195/4885RAB9A 380/4885NPC1 1355/4885 |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRNA10, ACHE, SNCA | KDM4E 1195/4885RAB9A 380/4885NPC1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.